These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 22310849)

  • 21. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.
    Lapuerta P; Rosenstock J; Zambrowicz B; Powell DR; Ogbaa I; Freiman J; Cefalu WT; Banks P; Frazier K; Kelly M; Sands A
    Clin Cardiol; 2013 Jul; 36(7):367-71. PubMed ID: 23630033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
    Pandey J; Tamrakar AK
    Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.
    Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S
    Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
    Zanoli L; Granata A; Lentini P; Rastelli S; Fatuzzo P; Rapisarda F; Castellino P
    ScientificWorldJournal; 2015; 2015():317507. PubMed ID: 25785281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
    Scheen AJ
    Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
    Yang J
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):747-753. PubMed ID: 30025475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
    Vallon V
    Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
    Freeman JS
    Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
    Zambrowicz B; Freiman J; Brown PM; Frazier KS; Turnage A; Bronner J; Ruff D; Shadoan M; Banks P; Mseeh F; Rawlins DB; Goodwin NC; Mabon R; Harrison BA; Wilson A; Sands A; Powell DR
    Clin Pharmacol Ther; 2012 Aug; 92(2):158-69. PubMed ID: 22739142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.